Disclosure of Interests

Allan Kember is the majority shareholder and the volunteer (unpaid) Chief Executive Officer and President of a startup company, Shiphrah Biomedical Inc. (SBI), which was one of the study funders. Allan Kember received financial payment from Mitacs through an entrepreneurship internship as part of his graduate studies at the University of Toronto (UofT). Min-En Hsieh received financial payment from Mitacs and UofT to complete an international exchange internship with SBI as part of his graduate studies at ​​National Cheng Kung University. The other authors report no conflict of interest.